|
Hyperprolactinemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Prevalence of macroprolactinemia was 21.57% (22/102) in hyperprolactinemia (prolactin >100 ng/ml).
|
30269265 |
2019 |
|
Hyperprolactinemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Non-gPRLoma was considered when tumor diameter was ≥ 10 mm and<40 mm associated to hyperprolactinemia (PRL≥200 ng/ml).
|
30396208 |
2018 |
|
Hyperprolactinemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The objective of this study was to estimate the association between hyperprolactinemia and all-cause and cardiovascular mortality among patients referred for assessment of prolactin.
|
28437810 |
2017 |
|
Hyperprolactinemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Prolactin gene polymorphism (-1149 G/T) is associated with hyperprolactinemia in patients with schizophrenia treated with antipsychotics.
|
27776952 |
2017 |
|
Hyperprolactinemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Dysregulation of the signaling pathways that govern lactotrope biology contributes to tumorigenesis of prolactin (PRL)-secreting adenomas, or prolactinomas, leading to a state of pathological hyperprolactinemia.
|
25472533 |
2015 |
|
Prolactinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We hypothesize that the alteration of PRL actions in lactotrope homeostasis due to the dysregulation of any of the mechanisms of actions described above may contribute to the pathogenesis of prolactinomas.
|
30376668 |
2019 |
|
Prolactinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Recently, our group found that 15-PGDH expression was low in prolactin (PRL) secreting adenomas (prolactinomas) and growth hormone (GH) secreting adenomas (GHomas) using fiber-optic BeadArray technology.
|
22580984 |
2012 |
|
Prolactinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Germline DNA samples of 131 Italian sporadic acromegalic patients including 38 individuals with multiple tumors, and of six FIPA families (four homogeneous for prolactinomas and two heterogeneous with prolactin/nonfunctioning pituitary adenomas) were collected in a multicentric collaborative study.
|
20530095 |
2010 |
|
Prolactinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We report a female with combined pituitary hormone deficiencies (GH, TSH, gonadotropin and ACTH), except for prolactin, as a consequence of PROP1 mutation, and a male with KS (anosmia and IHH) due to Kal 2 gene (fibroblast growth factor receptor 1- FGFR1) mutation, both of whom in adulthood presented with prolactinomas.
|
22801565 |
2013 |
|
Prolactinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Examples include: association of prolactinomas with paternal deprivation and with stressful life events; pseudocyesis; acute life event-driven episodes of galactorrhea; episodes of rapid weight gain following a life event; prolactin surges (without associated cortisol surges) following some psychological stresses.
|
31062250 |
2019 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
No specific TPIT immunostaining was detectable in all prolactin (PRL)-, GH-, or gonadotropin-secreting adenomas.
|
12843142 |
2003 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Ptx1 was detected in 10/14 (71.4%) of growth hormone (GH)-secreting adenomas, 12/12 (100%) of prolactin (PRL)-secreting adenomas, 18/20 (90%) of adrenocorticotropic hormone (ACTH)-secreting adenomas, 6/7 (85.7%) of thyroid-stimulating hormone (TSH)-secreting adenomas, and 17/20 (85%) of clinically non-functioning adenomas, including 9/10 (90%) of gonadotropin-subunit-positive adenomas.
|
11048804 |
2000 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A functional pituitary adenoma can produce multiple anterior-pituitary hormones, such as growth hormone (GH) -producing adenomas (GHoma) with prolactin or thyrotropin stimulating hormone production in the same lineage.
|
28865461 |
2017 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Four tumors were shown to have a hypotriploid chromosomal constitution, two of which also presented structural clonal rearrangements: an isochromosome 1q,i(1)(q10) and a der(1)t(1;3)(p22;q21) were observed in two PRL-secreting adenomas, one of which also had a telomeric association involving the short arms of chromosomes 14 and 19.
|
9332478 |
1997 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Dysregulation of the signaling pathways that govern lactotrope biology contributes to tumorigenesis of prolactin (PRL)-secreting adenomas, or prolactinomas, leading to a state of pathological hyperprolactinemia.
|
25472533 |
2015 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A comparative RT-PCR approach revealed signals for both V3 receptor and CHR receptor mRNAs in 17 of 18 ACTH-secreting pituitary adenomas, and 6 of 6 normal pituitaries; in six growth hormone- or prolactin-secreting adenomas, a very faint V3 receptor signal was observed in three cases, and CRH receptor signal was undetected in all.
|
8636444 |
1996 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In 35% of the cases the adenoma was nonfunctional, while in the others it was associated with PRL, GH and/or ACTH endocrine hypersecretion syndrome.
|
12011941 |
2002 |
|
Lupus Erythematosus, Systemic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Characterization of a prolactin gene polymorphism and its associations with systemic lupus erythematosus.
|
11665977 |
2001 |
|
Lupus Erythematosus, Systemic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our data demonstrate that the prolactin promoter polymorphism -1149 G/T does not significantly contribute to SLE disease susceptibility but does predispose carriers to other immunological changes.
|
21500962 |
2011 |
|
Lupus Erythematosus, Systemic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Moreover a panel of HLA typed SLE and control individuals were individually genotyped for the PRL G-1149T polymorphism previously described to be associated with SLE.
|
12559630 |
2003 |
|
Lupus Erythematosus, Systemic
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
This indicates a possible mechanism for the association of prolactin with SLE.
|
11721693 |
2001 |
|
Lupus Erythematosus, Systemic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
HLA class II, MICA and PRL gene polymorphisms: the common contribution to the systemic lupus erythematosus development in Czech population.
|
20352225 |
2011 |
|
Lupus Erythematosus, Systemic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PRL -1149 TT genotype is associated with susceptibility to SLE in a Mexican-Mestizo population, and high PRL serum levels are associated with anti-RNP antibodies and renal activity.
|
30154884 |
2018 |
|
Lupus Erythematosus, Systemic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Meta-analysis of associations between functional prolactin -1149 G/T polymorphism and susceptibility to rheumatoid arthritis and systemic lupus erythematosus.
|
25724680 |
2015 |
|
Lupus Erythematosus, Systemic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This preliminary study examined the relevance of a -1149G/T functional single-nucleotide polymorphism (SNP) (rs1341239) in the promoter of the extrapituitary prolactin gene in a cohort of African American and European American women with lupus.
|
26583155 |
2015 |